Reagan Udall Foundation for FDA Facilitates Discussion on Urgent Needs in PTSD Therapy
The Reagan Udall Foundation hosted a meeting on advancing PTSD treatments, highlighting the unmet need and discussing current clinical trials, including those for MDMA-assisted therapy. Participants emphasized the importance of representative clinical trials and the impact of trauma on lives, with some criticizing the FDA's handling of MDMA trials. Despite challenges, there is optimism for future advancements in PTSD treatment.
Highlighted Terms
Related News
The Reagan Udall Foundation hosted a meeting on advancing PTSD treatments, highlighting the unmet need and discussing current clinical trials, including those for MDMA-assisted therapy. Participants emphasized the importance of representative clinical trials and the impact of trauma on lives, with some criticizing the FDA's handling of MDMA trials. Despite challenges, there is optimism for future advancements in PTSD treatment.
FDA hybrid meeting on PTSD therapies highlighted the urgent need for innovative treatments, with MDMA-assisted therapy trials participants sharing healing stories. MAPS hosted a press briefing featuring key thought leaders advocating for the approval of psychedelic-assisted therapies for PTSD, emphasizing the need to close the 25-year gap on new pharmacotherapies.